TrialNature medicine2026

Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial.

Anna Morena D'Alise et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.